5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro

Tun, Mya Myat Ngwe; Sakura, Takaya; Sakurai, Yoshio; Kurosaki, Yohei; Inaoka, D.K.; Shioda, Norifumi; Smith, Chris; Yasuda, Jiro; Morita, Kouichi; Kita, Kiyoshi

doi:10.1186/s41182-022-00422-7

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The infected cell supernatant was quantified using qRT‐PCR described in previous reports [51,52] . To confirm our quantitative assay, the previously reported anti‐viral effects of remdesivir and virus‐containing medium were used as positive and negative controls (virus only), respectively [53–55] . The experiments were conducted in duplicate to determine the IC 50 .…”

Section: Methodsmentioning

confidence: 99%

Challenges Based on Antiplasmodial and Antiviral Activities of 7‐Chloro‐4‐aminoquinoline Derivatives

et al. 2023

Self Cite

View full text Add to dashboard Cite

We report the structural functionalization of the terminal amino group of N 1 -(7-chloroquinolin-4-yl) butane-1,4-diamine, leading to a series of 7-chloro-4-aminoquinoline derivatives, and their evaluation as potent anti-malarial and anti-viral agents. Some compounds exhibited promising anti-malarial effects against the Plasmodium falciparum 3D7 (chloroquine-sensitive) and Dd2 (chloroquine-resistant) strains. In addition, these compounds were assayed in vitro against influenza A virus (IAV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Compound 5 h, bearing an N-mesityl thiourea group, displayed pronounced anti-infectious effects against malaria, IAV, and SARS-CoV-2. These results provide new insights into drug discovery for the prevention or treatment of malaria and virus co-infection.

show abstract

Section: Methodsmentioning

confidence: 99%

Challenges Based on Antiplasmodial and Antiviral Activities of 7‐Chloro‐4‐aminoquinoline Derivatives

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, in vitro experiments with different SARS-CoV-2 strains showed that even low concentrations of 5-ALA with SFC inhibited replication of the Wuhan, alpha, and delta strains. Higher concentrations were effective against the beta and gamma strains[41].…”

mentioning

confidence: 95%

Safety and immune-supportive potential of the food supplement 5-aminolevulinic acid phosphate for patients with COVID-19: An open-label, non-randomized pilot study

Darwish,

Almadani,

Alsalman

et al. 2024

BCHD

View full text Add to dashboard Cite

Background: One mode of action of 5-ALA with SFC is the induction of Heme Oxygenase-1, a key regulator in anti-oxidative and immunological processes, leading to the hypothesis that the product supports faster recovery from infections such as COVID-19. Objective: The main objective was to assess the safety and immune-supportive potential of the food supplement 5-aminolevulinic acid phosphate (5-ALA) with sodium ferrous citrate (SFC) in patients with COVID-19 when co-administered with standard of care medications (SoC).Methods: A patient group with moderate COVID-19 symptoms (four males and three females, mean age 43 years) and one group with severe symptoms (12 males, mean age 48 years) received daily oral doses of 500 mg/750 mg 5-ALA with 286 mg/430 mg SFC for the first 7 days (≤7.5 times higher than the recommended dose for the marketed product). For the subsequent 21 d, the daily dose was reduced to 250 mg 5-ALA with 143 mg SFC in both groups. Adverse events and several immunological laboratory parameters were collected. Moreover, the mean hospital stay was compared with historical data of patients solely treated with SoC. Results: Two patients in the moderate group showed elevated liver enzymes; however, these seemed to be related to SoC. In the severe group, one patient experienced constipation. No serious adverse events were observed. In the severe group, a significant decrease of C-reactive protein (109.42 5.41 mg/L; p <0.005), procalcitonin (0.87 to 0.07 ng/mL; p <0.005), and interleukin 6 (20.07 to 5.06 pg/mL; p <0.05) and an increase of the cluster of differentiation 4 (250 to 880 cells/µl; p <0.05) and the cluster of differentiation 8 (190 to 623 cells/µL; p <0.05) were detected. The hospital stay of the severe group was markedly shorter (8 d only) than that of the control group (16 d).Conclusions: 5-ALA with SFC was evaluated as safe for administration in COVID-19 patients. Moreover, there were signals detecting its immune-supportive potential. The small number of included patients limits interpretation of the significance of the results; however, the study is useful in deciding future development strategies. Trial Registration: The study was registered on ClinicalTrials.gov (https://clinicaltrials.gov/) on September 06, 2020 (registration no. NCT04542850.Keywords: 5-aminolevulinic acid; COVID-19; SARS-CoV-2; food supplement

show abstract

Accelerated 5-aminolevulinic acid biosynthesis by coupling aconitase and ALA synthase in engineered Escherichia coli

Lai,

2024

Biochemical Engineering Journal

View full text Add to dashboard Cite

5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro

Cited by 4 publications

References 18 publications

Challenges Based on Antiplasmodial and Antiviral Activities of 7‐Chloro‐4‐aminoquinoline Derivatives

Challenges Based on Antiplasmodial and Antiviral Activities of 7‐Chloro‐4‐aminoquinoline Derivatives

Safety and immune-supportive potential of the food supplement 5-aminolevulinic acid phosphate for patients with COVID-19: An open-label, non-randomized pilot study

Accelerated 5-aminolevulinic acid biosynthesis by coupling aconitase and ALA synthase in engineered Escherichia coli

Contact Info

Product

Resources

About